Fabry Disease Clinical Trials

Find Fabry Disease Clinical Trials Near You

A Prospective, Open-label, Multicentre, Interventional, Single-arm, Phase IV Study to Evaluate the Safety and Efficacy of Replagal (Agalsidase Alfa [r-DNA Origin]) in Indian Children and Adults With Fabry Disease

Who is this study for? Indian children and adults with Fabry disease
What treatments are being studied? Replagal
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The main aim of this study is to learn more about the safety profile of Replagal. Participants will receive Replagal every 2 weeks at the clinic for about 1 year.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Male and female Replagal naïve participants (and who are not part of any other program that allows participant to get access to free enzyme replacement therapy \[ERT\] at the time of study enrollment and during the study period) of any age with confirmed diagnosis of Fabry disease.

• Participants who have documented confirmed diagnosis of Fabry disease based on proof of gene mutation: α-galactosidase A gene compatible with Fabry disease and/or a deficiency of α-galactosidase A (less than \[\<\] 4.0 nanomole per milliliter per hour (nmol/mL/hour) in plasma or serum or \<8 percent (%) of average mean normal in leukocytes and sequencing of GLA gene for females).

• Participant must have any clinical manifestations of Fabry disease based on investigator's discretion.

• Participant/legal authorized representative (LAR)/guardian is able to understand and willing to give written informed consent before performing any study specific procedures and willing to adhere to protocol requirements.

• Female participants of childbearing potential (example, nonsterilised, premenopausal female participants) must have a documented negative pregnancy test prior to administration of the first dose of Replagal in this study. In addition, all female participants of childbearing potential must use a two medically accepted forms of contraception throughout the study, that is, either a barrier method or hormonal contraceptive with norethindrone and ethinyl estradiol or similar active components.

• Male participant who is nonsterilised and sexually active with a female partner of childbearing potential agrees to use barrier method of contraception (example, condom with or without spermicide) from signing of informed consent throughout the duration of the study.

⁃ Note: Female participants not of childbearing potential defined as those who have been surgically sterilized (hysterectomy, bilateral oophorectomy, or tubal ligation) or who are postmenopausal (example, defined as at least 1 year since last regular menses with an appropriate clinical profile \[that is, age appropriate, history of vasomotor symptoms\]).

Locations
Other Locations
India
Institute of Child Health
NOT_YET_RECRUITING
Kolkata
All India Institute of Medical Sciences (AIIMS)
RECRUITING
New Delhi
Sir Gangaram Hospital
RECRUITING
New Delhi
Contact Information
Primary
Takeda Contact
ClinicalTransparency@takeda.com
+1 866 842 5335
Time Frame
Start Date: 2022-11-01
Estimated Completion Date: 2027-10-31
Participants
Target number of participants: 5
Treatments
Experimental: Replagal
Participants with fabry disease will receive Replagal 0.2 milligram per kilogram (mg/kg) intravenous infusion on Day 1 and every 2 weeks up to Week 51.
Authors
Priyanshu Mathur
Related Therapeutic Areas
Sponsors
Leads: Shire
Collaborators: Takeda

This content was sourced from clinicaltrials.gov

Similar Clinical Trials